Tecentriq®

Active substance

Atezolizumab

Holder

Roche

Status

Closed

Indication

in combination with bevacizumab, is indicated for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/04/2021